The Leukemia and Lymphoma Society (LLS) T-cells in Blood Cancer and COVID-19

Study summary

Five hundred (500) patients participating in the LLS COVID-19 Registry, who have shown either no antibody or limited antibody response by way of the Spike Antibody test to one of the vaccinations authorized for emergency use (EUA) by FDA will participate in the LLS T-cells, Blood Cancer and COVID-19 Clinical Research Study. They will be followed for at least ten years (in the COVID-19 Registry). In addition, 500 patients with similar blood cancer diagnosis, also participating in the LLS COVID-19 Registry, who have shown full Spike antibody response to one of the vaccinations authorized for emergency use (EUA) by FDA will also be enrolled the LLS T-cells, Blood Cancer and COVID-19 Clinical Research Study for comparison (as a control arm) and will also be followed for at least 10 years (in the COVID-19 Registry).

Ask AI to explain this study

Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedImmunoSEQ

The study team can explain what participation involves.

Who it may be forCovid-19

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Aug 17, 2022 · Source: ClinicalTrials.gov

Is enrollment open?Suspended

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Larry Saltzman, MD

Study sponsor

Study overview

What this study is about

Purpose: Not specified
Study type: Observational
Phase: Not applicable
Sponsor: Larry Saltzman, MD
Interventions being studied: Diagnostic Test: ImmunoSEQ

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Select patients participating in the LLS COVID-19 Registry will be invited to enroll

Reasons someone may not be able to joinExclusion criteria

People who have not participated in the LLS COVID-19 Registry

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Lymphoma and Leukemia SocietyRye Brook, New York

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 17, 2022. Always confirm current availability with the study team.

View original record ↗